February 2010 Volume 7 Number 2
Visit Nature Reviews Urology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=53&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Urology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=29&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=110&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
*********************************************************************
Nature Reviews Urology Impact Factor: 2.874*
(*Journal Citation Reports, Thomson, 2008)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Semen Analysis
Special Issue and Web Focus
The Asian Journal of Andrology is proud to present a special issue and
web focus on Semen Analysis which discusses some of the behind-the-scenes
controversies regarding the recommendations and guidelines for quality
control and interpretation set down in the latest edition of the World
Health Organization Laboratory Manual for the Examination of Human Semen
(5th edition).
For a limited-time, access select articles free of charge through the Special
Issue and Web Focus on Semen Analysis.
http://links.ealert.nature.com/ctt?kn=33&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
Prostate cancer: Post-diagnosis diet and the risk of progression
p57 | doi:10.1038/nrurol.2010.5
http://links.ealert.nature.com/ctt?kn=10&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Prostate cancer: Drug reduces hot flashes caused by hormone therapy
p58 | doi:10.1038/nrurol.2009.257
http://links.ealert.nature.com/ctt?kn=6&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
IN BRIEF
Prostate cancer | Surgery
p58 | doi:10.1038/nrurol.2009.260
http://links.ealert.nature.com/ctt?kn=8&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Chemotherapy: Satraplatin delays progression in prostate cancer
p59 | doi:10.1038/nrclinonc.2009.230
http://links.ealert.nature.com/ctt?kn=2&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Prostate cancer: Trimodal therapy a promising alternative for high-risk
patients
p59 | doi:10.1038/nrurol.2009.256
http://links.ealert.nature.com/ctt?kn=4&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
BPA worsens male sexual function
p60 | doi:10.1038/nrurol.2009.246
http://links.ealert.nature.com/ctt?kn=20&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Male factor infertility: Milestone in autotransplantation of human
spermatogonial stem cells
p60 | doi:10.1038/nrurol.2009.258
http://links.ealert.nature.com/ctt?kn=18&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
IN BRIEF
Surgery | Ethics
p61 | doi:10.1038/nrurol.2009.251
http://links.ealert.nature.com/ctt?kn=15&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Bladder cancer: 'OMC' regimen shows curative potential in selected patients
p61 | doi:10.1038/nrurol.2009.259
http://links.ealert.nature.com/ctt?kn=34&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Urinary tract obstruction: Metal stents for malignant ureteral obstruction
p62 | doi:10.1038/nrurol.2009.243
http://links.ealert.nature.com/ctt?kn=35&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Stones: Childhood urolithiasis: what are the presenting features?
p62 | doi:10.1038/nrurol.2009.244
http://links.ealert.nature.com/ctt?kn=36&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Kidney cancer: Neoadjuvant targeted therapies in renal cell carcinoma
Vincenzo Ficarra and Giacomo Novara
p63 | doi:10.1038/nrurol.2010.2
Neoadjuvant targeted therapy can be used in patients with unresectable
locally advanced, locally recurrent or metastatic renal cell carcinoma
to induce cytoreduction before surgical resection. The efficacy of this
multimodal therapy is still unproven, however, and must be balanced against
a potential higher risk of perioperative complications.
http://links.ealert.nature.com/ctt?kn=37&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Prostatitis: Predictive value of post-massage urine leukocyte count for AIP
Adam B. Murphy, Aisha K. Taylor and Robert B. Nadler
p65 | doi:10.1038/nrurol.2010.3
An article in The Journal of Urology addresses a frustrating feature of
PSA-based prostate cancer screening, namely the fact that PSA is a fairly
nonspecific marker for cancer. The authors provide a potential diagnostic
test for the most common non-cancer diagnosis on prostate biopsy-asymptomatic
inflammatory prostatitis (AIP)-and recommend its use as a means of avoiding
unnecessary prostate biopsies.
http://links.ealert.nature.com/ctt?kn=30&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Pediatrics: Combining antimuscarinics shows promise for overactive bladder
Jean-Jacques Wyndaele
p66 | doi:10.1038/nrurol.2010.1
Antimuscarinic therapy for children with overactive or neurogenic bladder
is limited by its suboptimal efficacy and tolerability. New research suggests
that double antimuscarinic treatment can improve continence and urodynamic
parameters with an acceptable rate of adverse effects. Although the study
was small and uncontrolled, it provides the impetus for larger randomized
double-blind analyses.
http://links.ealert.nature.com/ctt?kn=31&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Imaging angiogenesis of genitourinary tumors
Ying-Kiat Zee, James P. B. O'Connor, Geoff J. M. Parker, Alan Jackson,
Andrew R. Clamp, M. Ben Taylor, Noel W. Clarke and Gordon C. Jayson
Published online: 19 January 2010
p69 | doi:10.1038/nrurol.2009.262
The targeting of angiogenesis is a growing area of cancer therapy. In vivo
imaging techniques allow the noninvasive evaluation of changes in tumor
vasculature in response to antiangiogenic agents. Zee et al. provide an
overview of MRI, CT, PET and ultrasound techniques, highlighting their
application in renal, prostate and bladder cancer.
Abstract: http://links.ealert.nature.com/ctt?kn=32&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=39&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors
Samdeep K. Mouli, Lee C. Zhao, Reed A. Omary and C. Shad Thaxton
Published online: 19 January 2010
p84 | doi:10.1038/nrurol.2009.254
Current imaging modalities lack sufficient sensitivity and specificity
for the noninvasive staging of lymph nodes in genitourinary cancers. In
this Review, Mouli and colleagues from Northwestern University discuss
the potential role of lymphotropic nanoparticles-which selectively accumulate
in benign lymph nodes-in enhancing the MRI detection of nodal metastases.
Abstract: http://links.ealert.nature.com/ctt?kn=38&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=41&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Testicular germline stem cells
Kehkooi Kee, Renee A. Reijo Pera and Paul J. Turek
Published online: 19 January 2010
p94 | doi:10.1038/nrurol.2009.263
In this Review, the authors discuss the potential of testicular germline
stem cells as a substrate for cell-based therapies. Although at an early
stage, research in this field is progressing rapidly. If their promise
is fulfilled, such cells could be applied to a range of therapeutic
indications, including tissue reconstruction and fertility restoration.
Abstract: http://links.ealert.nature.com/ctt?kn=40&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=44&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Urine biomarkers in prostate cancer
Guillaume Ploussard and Alexandre de la Taille
Published online: 12 January 2010
p101 | doi:10.1038/nrurol.2009.261
The publication last year of large trials of PSA screening in prostate
cancer has rekindled interest in alternative noninvasive markers for this
disease. Here, Ploussard and de la Taille discuss the range of potential
urinary biomarkers in prostate cancer, and the current clinical data on
their utility in disease detection and staging.
Abstract: http://links.ealert.nature.com/ctt?kn=45&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=42&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Renal medullary-like carcinoma in an adult without sickle cell
hemoglobinopathy
Peter H. O'Donnell, Ana Jensen, Edwin M. Posadas, Julia A. Bridge,
Anjana V. Yeldandi, Ximing J. Yang, Walter M. Stadler and Hikmat Al-Ahmadie
p110 | doi:10.1038/nrurol.2009.255
Renal medullary carcinoma has been almost exclusively diagnosed in patients
with sickle cell anemia. O'Donnell et al. present a case of this rare and
aggressive cancer in an adult with no detectable hemoglobinopathies. They
describe both the histopathological features of the disease, and the
systemic chemotherapies used to treat it.
Abstract: http://links.ealert.nature.com/ctt?kn=43&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=46&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
nature.com Open Innovation Pavilion
Solve for a cause!
Nature Publishing Group is proud to sponsor a Challenge by the Drugs for
Neglected Diseases initiative. Your ideas to solve this Challenge can help
change the lives of those suffering from African sleeping sickness, Chagas
disease or Leishmaniasis.
Visit http://links.ealert.nature.com/ctt?kn=28&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
to read more about this Challenge and how you can help.
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=78&m=34619412&r=MTc2NDg0NjM5NAS2&b=2&j=NjcxNTMyNjQS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2010 Nature Publishing Group
=====================================================================
